Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Portfolio Pulse from
Akero Therapeutics' stock surged over 100% following positive results from its phase 2b SYMMETRY study, showing significant reversal of cirrhosis in F4 MASH patients using EFX. The company plans further studies with results expected in 2026 and 2027.
January 28, 2025 | 7:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics' stock surged over 100% after its phase 2b SYMMETRY study showed EFX significantly reverses cirrhosis in F4 MASH patients. This marks a major milestone in treatment efficacy.
The stock price of Akero Therapeutics surged due to the positive results from the phase 2b SYMMETRY study, which demonstrated the efficacy of EFX in reversing cirrhosis in F4 MASH patients. This breakthrough is a significant development in the treatment of MASH, leading to increased investor confidence and a substantial rise in stock value.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100